The following antibodies were used in this study: anti-centromere antibody (ACA; or CREST-ImmunoVision; HCT-0100), anti-Myc (Roche; 11667203001), anti-Smc1 (Bethyl; A300-055A), anti-Rpb1 (Abcam; ab5408), anti-H3K4me2 (EMD Millipore; 07–030), anti-H3K9me3 (Abcam; ab8898), anti-Actin (Invitrogen; MA5-11869), anti-CENP-B (Abcam; ab25734), anti–CENP-A (EMD Millipore; 07–574), and anti–Rpb2-pSer2 (BioLegend; H5). Anti-Sgo1, anti-Bub1, and anti-Wapl were made in-house as described previously (Liu et al., 2013a (link); Qu et al., 2019 (link)). Anti-Sororin antibodies described previously were a gift from Dr. Susannah Rankin at Oklahoma Medical Research Foundation, Oklahoma City, OK (Liu et al., 2013b (link)).
The secondary antibodies were purchased from LI-COR: Goat anti-Mouse IgG Secondary Antibody (926–68070) and Goat anti-Rabbit IgG Secondary Antibody (926–32211).
For immunoblotting, primary and secondary antibodies were used at 1-µg ml−1 concentration.
The secondary antibodies were purchased from LI-COR: Goat anti-Mouse IgG Secondary Antibody (926–68070) and Goat anti-Rabbit IgG Secondary Antibody (926–32211).
For immunoblotting, primary and secondary antibodies were used at 1-µg ml−1 concentration.
Free full text: Click here
